Individual cell‐based modeling of tumor cell plasticity‐induced immune escape after CAR‐T therapy
Abstract Chimeric antigen receptor (CAR) therapy targeting CD19 is an effective treatment for refractory B cell malignancies, especially B‐cell acute lymphoblastic leukemia (B‐ALL). The majority of patients achieve a complete response following a single infusion of CD19‐targeted CAR‐modified T cells...
Ausführliche Beschreibung
Autor*in: |
Can Zhang [verfasserIn] Changrong Shao [verfasserIn] Xiaopei Jiao [verfasserIn] Yue Bai [verfasserIn] Miao Li [verfasserIn] Hanping Shi [verfasserIn] Jinzhi Lei [verfasserIn] Xiaosong Zhong [verfasserIn] |
---|
Format: |
E-Artikel |
---|---|
Sprache: |
Englisch |
Erschienen: |
2021 |
---|
Schlagwörter: |
---|
Übergeordnetes Werk: |
In: Computational and Systems Oncology - Wiley, 2021, 1(2021), 3, Seite n/a-n/a |
---|---|
Übergeordnetes Werk: |
volume:1 ; year:2021 ; number:3 ; pages:n/a-n/a |
Links: |
---|
DOI / URN: |
10.1002/cso2.1029 |
---|
Katalog-ID: |
DOAJ06271841X |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | DOAJ06271841X | ||
003 | DE-627 | ||
005 | 20230309022646.0 | ||
007 | cr uuu---uuuuu | ||
008 | 230228s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1002/cso2.1029 |2 doi | |
035 | |a (DE-627)DOAJ06271841X | ||
035 | |a (DE-599)DOAJebaa24c0803b4f1d8833b7c316639ecf | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
050 | 0 | |a RC254-282 | |
050 | 0 | |a R858-859.7 | |
100 | 0 | |a Can Zhang |e verfasserin |4 aut | |
245 | 1 | 0 | |a Individual cell‐based modeling of tumor cell plasticity‐induced immune escape after CAR‐T therapy |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Abstract Chimeric antigen receptor (CAR) therapy targeting CD19 is an effective treatment for refractory B cell malignancies, especially B‐cell acute lymphoblastic leukemia (B‐ALL). The majority of patients achieve a complete response following a single infusion of CD19‐targeted CAR‐modified T cells (CAR‐19 T cells); however, many patients suffer relapse after therapy, and the underlying mechanism remains unclear. To better understand the mechanism of tumor relapse, we developed an individual cell‐based computational model based on major assumptions of the tumor cells heterogeneity and plasticity as well as the heterogeneous responses to CAR‐T treatment. Model simulations reproduced the process of tumor relapse and predicted that cell plasticity induced by CAR‐T stress can lead to tumor relapse in B‐ALL. Model predictions were in agreement with experimental results of applying the second‐generation CAR‐T cells to mice injected with NALM‐6‐GL leukemic cells, in which 60% of the mice relapse within 3 months, relapsed tumors retained CD19 expression but exhibited a subpopulation of cells with high level CD34 transcription. The computational model suggests that the experimental data are compatible with a CAR‐T cell‐induced transition of tumor cells to hematopoietic stem‐like cells and myeloid‐like cells, which are resistant to the treatment. The proposed computational model framework was successfully developed to recapitulate the individual evolutionary dynamics and potentially allows to predict the outcomes of CAR‐T treatment through model simulation based on early‐stage observations of tumor burden and tumor cells analysis. | ||
650 | 4 | |a B‐cell acute lymphoblastic leukemia | |
650 | 4 | |a cancer immunotherapy | |
650 | 4 | |a CAR‐T | |
650 | 4 | |a cell plasticity | |
650 | 4 | |a immune escape | |
650 | 4 | |a individual cell‐based modeling | |
653 | 0 | |a Neoplasms. Tumors. Oncology. Including cancer and carcinogens | |
653 | 0 | |a Computer applications to medicine. Medical informatics | |
700 | 0 | |a Changrong Shao |e verfasserin |4 aut | |
700 | 0 | |a Xiaopei Jiao |e verfasserin |4 aut | |
700 | 0 | |a Yue Bai |e verfasserin |4 aut | |
700 | 0 | |a Miao Li |e verfasserin |4 aut | |
700 | 0 | |a Hanping Shi |e verfasserin |4 aut | |
700 | 0 | |a Jinzhi Lei |e verfasserin |4 aut | |
700 | 0 | |a Xiaosong Zhong |e verfasserin |4 aut | |
773 | 0 | 8 | |i In |t Computational and Systems Oncology |d Wiley, 2021 |g 1(2021), 3, Seite n/a-n/a |w (DE-627)1753559456 |w (DE-600)3059855-2 |x 26899655 |7 nnns |
773 | 1 | 8 | |g volume:1 |g year:2021 |g number:3 |g pages:n/a-n/a |
856 | 4 | 0 | |u https://doi.org/10.1002/cso2.1029 |z kostenfrei |
856 | 4 | 0 | |u https://doaj.org/article/ebaa24c0803b4f1d8833b7c316639ecf |z kostenfrei |
856 | 4 | 0 | |u https://doi.org/10.1002/cso2.1029 |z kostenfrei |
856 | 4 | 2 | |u https://doaj.org/toc/2689-9655 |y Journal toc |z kostenfrei |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_DOAJ | ||
912 | |a GBV_ILN_20 | ||
912 | |a GBV_ILN_22 | ||
912 | |a GBV_ILN_23 | ||
912 | |a GBV_ILN_24 | ||
912 | |a GBV_ILN_31 | ||
912 | |a GBV_ILN_39 | ||
912 | |a GBV_ILN_40 | ||
912 | |a GBV_ILN_60 | ||
912 | |a GBV_ILN_62 | ||
912 | |a GBV_ILN_63 | ||
912 | |a GBV_ILN_65 | ||
912 | |a GBV_ILN_69 | ||
912 | |a GBV_ILN_73 | ||
912 | |a GBV_ILN_74 | ||
912 | |a GBV_ILN_95 | ||
912 | |a GBV_ILN_105 | ||
912 | |a GBV_ILN_110 | ||
912 | |a GBV_ILN_151 | ||
912 | |a GBV_ILN_161 | ||
912 | |a GBV_ILN_170 | ||
912 | |a GBV_ILN_171 | ||
912 | |a GBV_ILN_206 | ||
912 | |a GBV_ILN_213 | ||
912 | |a GBV_ILN_224 | ||
912 | |a GBV_ILN_230 | ||
912 | |a GBV_ILN_285 | ||
912 | |a GBV_ILN_293 | ||
912 | |a GBV_ILN_602 | ||
912 | |a GBV_ILN_636 | ||
912 | |a GBV_ILN_2004 | ||
912 | |a GBV_ILN_2005 | ||
912 | |a GBV_ILN_2006 | ||
912 | |a GBV_ILN_2007 | ||
912 | |a GBV_ILN_2010 | ||
912 | |a GBV_ILN_2011 | ||
912 | |a GBV_ILN_2014 | ||
912 | |a GBV_ILN_2026 | ||
912 | |a GBV_ILN_2027 | ||
912 | |a GBV_ILN_2034 | ||
912 | |a GBV_ILN_2037 | ||
912 | |a GBV_ILN_2038 | ||
912 | |a GBV_ILN_2044 | ||
912 | |a GBV_ILN_2048 | ||
912 | |a GBV_ILN_2049 | ||
912 | |a GBV_ILN_2050 | ||
912 | |a GBV_ILN_2055 | ||
912 | |a GBV_ILN_2056 | ||
912 | |a GBV_ILN_2057 | ||
912 | |a GBV_ILN_2059 | ||
912 | |a GBV_ILN_2061 | ||
912 | |a GBV_ILN_2064 | ||
912 | |a GBV_ILN_2068 | ||
912 | |a GBV_ILN_2088 | ||
912 | |a GBV_ILN_2106 | ||
912 | |a GBV_ILN_2108 | ||
912 | |a GBV_ILN_2110 | ||
912 | |a GBV_ILN_2111 | ||
912 | |a GBV_ILN_2118 | ||
912 | |a GBV_ILN_2122 | ||
912 | |a GBV_ILN_2143 | ||
912 | |a GBV_ILN_2144 | ||
912 | |a GBV_ILN_2147 | ||
912 | |a GBV_ILN_2148 | ||
912 | |a GBV_ILN_2152 | ||
912 | |a GBV_ILN_2153 | ||
912 | |a GBV_ILN_2232 | ||
912 | |a GBV_ILN_2336 | ||
912 | |a GBV_ILN_2470 | ||
912 | |a GBV_ILN_2507 | ||
912 | |a GBV_ILN_2522 | ||
912 | |a GBV_ILN_4012 | ||
912 | |a GBV_ILN_4035 | ||
912 | |a GBV_ILN_4037 | ||
912 | |a GBV_ILN_4046 | ||
912 | |a GBV_ILN_4112 | ||
912 | |a GBV_ILN_4125 | ||
912 | |a GBV_ILN_4126 | ||
912 | |a GBV_ILN_4242 | ||
912 | |a GBV_ILN_4249 | ||
912 | |a GBV_ILN_4251 | ||
912 | |a GBV_ILN_4305 | ||
912 | |a GBV_ILN_4306 | ||
912 | |a GBV_ILN_4307 | ||
912 | |a GBV_ILN_4313 | ||
912 | |a GBV_ILN_4322 | ||
912 | |a GBV_ILN_4323 | ||
912 | |a GBV_ILN_4324 | ||
912 | |a GBV_ILN_4325 | ||
912 | |a GBV_ILN_4326 | ||
912 | |a GBV_ILN_4333 | ||
912 | |a GBV_ILN_4334 | ||
912 | |a GBV_ILN_4335 | ||
912 | |a GBV_ILN_4336 | ||
912 | |a GBV_ILN_4338 | ||
912 | |a GBV_ILN_4367 | ||
912 | |a GBV_ILN_4700 | ||
951 | |a AR | ||
952 | |d 1 |j 2021 |e 3 |h n/a-n/a |
author_variant |
c z cz c s cs x j xj y b yb m l ml h s hs j l jl x z xz |
---|---|
matchkey_str |
article:26899655:2021----::niiulelaemdlnotmrellsiiynueimn |
hierarchy_sort_str |
2021 |
callnumber-subject-code |
RC |
publishDate |
2021 |
allfields |
10.1002/cso2.1029 doi (DE-627)DOAJ06271841X (DE-599)DOAJebaa24c0803b4f1d8833b7c316639ecf DE-627 ger DE-627 rakwb eng RC254-282 R858-859.7 Can Zhang verfasserin aut Individual cell‐based modeling of tumor cell plasticity‐induced immune escape after CAR‐T therapy 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Chimeric antigen receptor (CAR) therapy targeting CD19 is an effective treatment for refractory B cell malignancies, especially B‐cell acute lymphoblastic leukemia (B‐ALL). The majority of patients achieve a complete response following a single infusion of CD19‐targeted CAR‐modified T cells (CAR‐19 T cells); however, many patients suffer relapse after therapy, and the underlying mechanism remains unclear. To better understand the mechanism of tumor relapse, we developed an individual cell‐based computational model based on major assumptions of the tumor cells heterogeneity and plasticity as well as the heterogeneous responses to CAR‐T treatment. Model simulations reproduced the process of tumor relapse and predicted that cell plasticity induced by CAR‐T stress can lead to tumor relapse in B‐ALL. Model predictions were in agreement with experimental results of applying the second‐generation CAR‐T cells to mice injected with NALM‐6‐GL leukemic cells, in which 60% of the mice relapse within 3 months, relapsed tumors retained CD19 expression but exhibited a subpopulation of cells with high level CD34 transcription. The computational model suggests that the experimental data are compatible with a CAR‐T cell‐induced transition of tumor cells to hematopoietic stem‐like cells and myeloid‐like cells, which are resistant to the treatment. The proposed computational model framework was successfully developed to recapitulate the individual evolutionary dynamics and potentially allows to predict the outcomes of CAR‐T treatment through model simulation based on early‐stage observations of tumor burden and tumor cells analysis. B‐cell acute lymphoblastic leukemia cancer immunotherapy CAR‐T cell plasticity immune escape individual cell‐based modeling Neoplasms. Tumors. Oncology. Including cancer and carcinogens Computer applications to medicine. Medical informatics Changrong Shao verfasserin aut Xiaopei Jiao verfasserin aut Yue Bai verfasserin aut Miao Li verfasserin aut Hanping Shi verfasserin aut Jinzhi Lei verfasserin aut Xiaosong Zhong verfasserin aut In Computational and Systems Oncology Wiley, 2021 1(2021), 3, Seite n/a-n/a (DE-627)1753559456 (DE-600)3059855-2 26899655 nnns volume:1 year:2021 number:3 pages:n/a-n/a https://doi.org/10.1002/cso2.1029 kostenfrei https://doaj.org/article/ebaa24c0803b4f1d8833b7c316639ecf kostenfrei https://doi.org/10.1002/cso2.1029 kostenfrei https://doaj.org/toc/2689-9655 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_206 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_636 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2068 GBV_ILN_2088 GBV_ILN_2106 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2118 GBV_ILN_2122 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2470 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_4012 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 1 2021 3 n/a-n/a |
spelling |
10.1002/cso2.1029 doi (DE-627)DOAJ06271841X (DE-599)DOAJebaa24c0803b4f1d8833b7c316639ecf DE-627 ger DE-627 rakwb eng RC254-282 R858-859.7 Can Zhang verfasserin aut Individual cell‐based modeling of tumor cell plasticity‐induced immune escape after CAR‐T therapy 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Chimeric antigen receptor (CAR) therapy targeting CD19 is an effective treatment for refractory B cell malignancies, especially B‐cell acute lymphoblastic leukemia (B‐ALL). The majority of patients achieve a complete response following a single infusion of CD19‐targeted CAR‐modified T cells (CAR‐19 T cells); however, many patients suffer relapse after therapy, and the underlying mechanism remains unclear. To better understand the mechanism of tumor relapse, we developed an individual cell‐based computational model based on major assumptions of the tumor cells heterogeneity and plasticity as well as the heterogeneous responses to CAR‐T treatment. Model simulations reproduced the process of tumor relapse and predicted that cell plasticity induced by CAR‐T stress can lead to tumor relapse in B‐ALL. Model predictions were in agreement with experimental results of applying the second‐generation CAR‐T cells to mice injected with NALM‐6‐GL leukemic cells, in which 60% of the mice relapse within 3 months, relapsed tumors retained CD19 expression but exhibited a subpopulation of cells with high level CD34 transcription. The computational model suggests that the experimental data are compatible with a CAR‐T cell‐induced transition of tumor cells to hematopoietic stem‐like cells and myeloid‐like cells, which are resistant to the treatment. The proposed computational model framework was successfully developed to recapitulate the individual evolutionary dynamics and potentially allows to predict the outcomes of CAR‐T treatment through model simulation based on early‐stage observations of tumor burden and tumor cells analysis. B‐cell acute lymphoblastic leukemia cancer immunotherapy CAR‐T cell plasticity immune escape individual cell‐based modeling Neoplasms. Tumors. Oncology. Including cancer and carcinogens Computer applications to medicine. Medical informatics Changrong Shao verfasserin aut Xiaopei Jiao verfasserin aut Yue Bai verfasserin aut Miao Li verfasserin aut Hanping Shi verfasserin aut Jinzhi Lei verfasserin aut Xiaosong Zhong verfasserin aut In Computational and Systems Oncology Wiley, 2021 1(2021), 3, Seite n/a-n/a (DE-627)1753559456 (DE-600)3059855-2 26899655 nnns volume:1 year:2021 number:3 pages:n/a-n/a https://doi.org/10.1002/cso2.1029 kostenfrei https://doaj.org/article/ebaa24c0803b4f1d8833b7c316639ecf kostenfrei https://doi.org/10.1002/cso2.1029 kostenfrei https://doaj.org/toc/2689-9655 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_206 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_636 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2068 GBV_ILN_2088 GBV_ILN_2106 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2118 GBV_ILN_2122 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2470 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_4012 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 1 2021 3 n/a-n/a |
allfields_unstemmed |
10.1002/cso2.1029 doi (DE-627)DOAJ06271841X (DE-599)DOAJebaa24c0803b4f1d8833b7c316639ecf DE-627 ger DE-627 rakwb eng RC254-282 R858-859.7 Can Zhang verfasserin aut Individual cell‐based modeling of tumor cell plasticity‐induced immune escape after CAR‐T therapy 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Chimeric antigen receptor (CAR) therapy targeting CD19 is an effective treatment for refractory B cell malignancies, especially B‐cell acute lymphoblastic leukemia (B‐ALL). The majority of patients achieve a complete response following a single infusion of CD19‐targeted CAR‐modified T cells (CAR‐19 T cells); however, many patients suffer relapse after therapy, and the underlying mechanism remains unclear. To better understand the mechanism of tumor relapse, we developed an individual cell‐based computational model based on major assumptions of the tumor cells heterogeneity and plasticity as well as the heterogeneous responses to CAR‐T treatment. Model simulations reproduced the process of tumor relapse and predicted that cell plasticity induced by CAR‐T stress can lead to tumor relapse in B‐ALL. Model predictions were in agreement with experimental results of applying the second‐generation CAR‐T cells to mice injected with NALM‐6‐GL leukemic cells, in which 60% of the mice relapse within 3 months, relapsed tumors retained CD19 expression but exhibited a subpopulation of cells with high level CD34 transcription. The computational model suggests that the experimental data are compatible with a CAR‐T cell‐induced transition of tumor cells to hematopoietic stem‐like cells and myeloid‐like cells, which are resistant to the treatment. The proposed computational model framework was successfully developed to recapitulate the individual evolutionary dynamics and potentially allows to predict the outcomes of CAR‐T treatment through model simulation based on early‐stage observations of tumor burden and tumor cells analysis. B‐cell acute lymphoblastic leukemia cancer immunotherapy CAR‐T cell plasticity immune escape individual cell‐based modeling Neoplasms. Tumors. Oncology. Including cancer and carcinogens Computer applications to medicine. Medical informatics Changrong Shao verfasserin aut Xiaopei Jiao verfasserin aut Yue Bai verfasserin aut Miao Li verfasserin aut Hanping Shi verfasserin aut Jinzhi Lei verfasserin aut Xiaosong Zhong verfasserin aut In Computational and Systems Oncology Wiley, 2021 1(2021), 3, Seite n/a-n/a (DE-627)1753559456 (DE-600)3059855-2 26899655 nnns volume:1 year:2021 number:3 pages:n/a-n/a https://doi.org/10.1002/cso2.1029 kostenfrei https://doaj.org/article/ebaa24c0803b4f1d8833b7c316639ecf kostenfrei https://doi.org/10.1002/cso2.1029 kostenfrei https://doaj.org/toc/2689-9655 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_206 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_636 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2068 GBV_ILN_2088 GBV_ILN_2106 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2118 GBV_ILN_2122 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2470 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_4012 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 1 2021 3 n/a-n/a |
allfieldsGer |
10.1002/cso2.1029 doi (DE-627)DOAJ06271841X (DE-599)DOAJebaa24c0803b4f1d8833b7c316639ecf DE-627 ger DE-627 rakwb eng RC254-282 R858-859.7 Can Zhang verfasserin aut Individual cell‐based modeling of tumor cell plasticity‐induced immune escape after CAR‐T therapy 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Chimeric antigen receptor (CAR) therapy targeting CD19 is an effective treatment for refractory B cell malignancies, especially B‐cell acute lymphoblastic leukemia (B‐ALL). The majority of patients achieve a complete response following a single infusion of CD19‐targeted CAR‐modified T cells (CAR‐19 T cells); however, many patients suffer relapse after therapy, and the underlying mechanism remains unclear. To better understand the mechanism of tumor relapse, we developed an individual cell‐based computational model based on major assumptions of the tumor cells heterogeneity and plasticity as well as the heterogeneous responses to CAR‐T treatment. Model simulations reproduced the process of tumor relapse and predicted that cell plasticity induced by CAR‐T stress can lead to tumor relapse in B‐ALL. Model predictions were in agreement with experimental results of applying the second‐generation CAR‐T cells to mice injected with NALM‐6‐GL leukemic cells, in which 60% of the mice relapse within 3 months, relapsed tumors retained CD19 expression but exhibited a subpopulation of cells with high level CD34 transcription. The computational model suggests that the experimental data are compatible with a CAR‐T cell‐induced transition of tumor cells to hematopoietic stem‐like cells and myeloid‐like cells, which are resistant to the treatment. The proposed computational model framework was successfully developed to recapitulate the individual evolutionary dynamics and potentially allows to predict the outcomes of CAR‐T treatment through model simulation based on early‐stage observations of tumor burden and tumor cells analysis. B‐cell acute lymphoblastic leukemia cancer immunotherapy CAR‐T cell plasticity immune escape individual cell‐based modeling Neoplasms. Tumors. Oncology. Including cancer and carcinogens Computer applications to medicine. Medical informatics Changrong Shao verfasserin aut Xiaopei Jiao verfasserin aut Yue Bai verfasserin aut Miao Li verfasserin aut Hanping Shi verfasserin aut Jinzhi Lei verfasserin aut Xiaosong Zhong verfasserin aut In Computational and Systems Oncology Wiley, 2021 1(2021), 3, Seite n/a-n/a (DE-627)1753559456 (DE-600)3059855-2 26899655 nnns volume:1 year:2021 number:3 pages:n/a-n/a https://doi.org/10.1002/cso2.1029 kostenfrei https://doaj.org/article/ebaa24c0803b4f1d8833b7c316639ecf kostenfrei https://doi.org/10.1002/cso2.1029 kostenfrei https://doaj.org/toc/2689-9655 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_206 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_636 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2068 GBV_ILN_2088 GBV_ILN_2106 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2118 GBV_ILN_2122 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2470 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_4012 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 1 2021 3 n/a-n/a |
allfieldsSound |
10.1002/cso2.1029 doi (DE-627)DOAJ06271841X (DE-599)DOAJebaa24c0803b4f1d8833b7c316639ecf DE-627 ger DE-627 rakwb eng RC254-282 R858-859.7 Can Zhang verfasserin aut Individual cell‐based modeling of tumor cell plasticity‐induced immune escape after CAR‐T therapy 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Chimeric antigen receptor (CAR) therapy targeting CD19 is an effective treatment for refractory B cell malignancies, especially B‐cell acute lymphoblastic leukemia (B‐ALL). The majority of patients achieve a complete response following a single infusion of CD19‐targeted CAR‐modified T cells (CAR‐19 T cells); however, many patients suffer relapse after therapy, and the underlying mechanism remains unclear. To better understand the mechanism of tumor relapse, we developed an individual cell‐based computational model based on major assumptions of the tumor cells heterogeneity and plasticity as well as the heterogeneous responses to CAR‐T treatment. Model simulations reproduced the process of tumor relapse and predicted that cell plasticity induced by CAR‐T stress can lead to tumor relapse in B‐ALL. Model predictions were in agreement with experimental results of applying the second‐generation CAR‐T cells to mice injected with NALM‐6‐GL leukemic cells, in which 60% of the mice relapse within 3 months, relapsed tumors retained CD19 expression but exhibited a subpopulation of cells with high level CD34 transcription. The computational model suggests that the experimental data are compatible with a CAR‐T cell‐induced transition of tumor cells to hematopoietic stem‐like cells and myeloid‐like cells, which are resistant to the treatment. The proposed computational model framework was successfully developed to recapitulate the individual evolutionary dynamics and potentially allows to predict the outcomes of CAR‐T treatment through model simulation based on early‐stage observations of tumor burden and tumor cells analysis. B‐cell acute lymphoblastic leukemia cancer immunotherapy CAR‐T cell plasticity immune escape individual cell‐based modeling Neoplasms. Tumors. Oncology. Including cancer and carcinogens Computer applications to medicine. Medical informatics Changrong Shao verfasserin aut Xiaopei Jiao verfasserin aut Yue Bai verfasserin aut Miao Li verfasserin aut Hanping Shi verfasserin aut Jinzhi Lei verfasserin aut Xiaosong Zhong verfasserin aut In Computational and Systems Oncology Wiley, 2021 1(2021), 3, Seite n/a-n/a (DE-627)1753559456 (DE-600)3059855-2 26899655 nnns volume:1 year:2021 number:3 pages:n/a-n/a https://doi.org/10.1002/cso2.1029 kostenfrei https://doaj.org/article/ebaa24c0803b4f1d8833b7c316639ecf kostenfrei https://doi.org/10.1002/cso2.1029 kostenfrei https://doaj.org/toc/2689-9655 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_206 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_636 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2068 GBV_ILN_2088 GBV_ILN_2106 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2118 GBV_ILN_2122 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2470 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_4012 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 1 2021 3 n/a-n/a |
language |
English |
source |
In Computational and Systems Oncology 1(2021), 3, Seite n/a-n/a volume:1 year:2021 number:3 pages:n/a-n/a |
sourceStr |
In Computational and Systems Oncology 1(2021), 3, Seite n/a-n/a volume:1 year:2021 number:3 pages:n/a-n/a |
format_phy_str_mv |
Article |
institution |
findex.gbv.de |
topic_facet |
B‐cell acute lymphoblastic leukemia cancer immunotherapy CAR‐T cell plasticity immune escape individual cell‐based modeling Neoplasms. Tumors. Oncology. Including cancer and carcinogens Computer applications to medicine. Medical informatics |
isfreeaccess_bool |
true |
container_title |
Computational and Systems Oncology |
authorswithroles_txt_mv |
Can Zhang @@aut@@ Changrong Shao @@aut@@ Xiaopei Jiao @@aut@@ Yue Bai @@aut@@ Miao Li @@aut@@ Hanping Shi @@aut@@ Jinzhi Lei @@aut@@ Xiaosong Zhong @@aut@@ |
publishDateDaySort_date |
2021-01-01T00:00:00Z |
hierarchy_top_id |
1753559456 |
id |
DOAJ06271841X |
language_de |
englisch |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ06271841X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230309022646.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230228s2021 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1002/cso2.1029</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ06271841X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJebaa24c0803b4f1d8833b7c316639ecf</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC254-282</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">R858-859.7</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Can Zhang</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Individual cell‐based modeling of tumor cell plasticity‐induced immune escape after CAR‐T therapy</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Chimeric antigen receptor (CAR) therapy targeting CD19 is an effective treatment for refractory B cell malignancies, especially B‐cell acute lymphoblastic leukemia (B‐ALL). The majority of patients achieve a complete response following a single infusion of CD19‐targeted CAR‐modified T cells (CAR‐19 T cells); however, many patients suffer relapse after therapy, and the underlying mechanism remains unclear. To better understand the mechanism of tumor relapse, we developed an individual cell‐based computational model based on major assumptions of the tumor cells heterogeneity and plasticity as well as the heterogeneous responses to CAR‐T treatment. Model simulations reproduced the process of tumor relapse and predicted that cell plasticity induced by CAR‐T stress can lead to tumor relapse in B‐ALL. Model predictions were in agreement with experimental results of applying the second‐generation CAR‐T cells to mice injected with NALM‐6‐GL leukemic cells, in which 60% of the mice relapse within 3 months, relapsed tumors retained CD19 expression but exhibited a subpopulation of cells with high level CD34 transcription. The computational model suggests that the experimental data are compatible with a CAR‐T cell‐induced transition of tumor cells to hematopoietic stem‐like cells and myeloid‐like cells, which are resistant to the treatment. The proposed computational model framework was successfully developed to recapitulate the individual evolutionary dynamics and potentially allows to predict the outcomes of CAR‐T treatment through model simulation based on early‐stage observations of tumor burden and tumor cells analysis.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">B‐cell acute lymphoblastic leukemia</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">cancer immunotherapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">CAR‐T</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">cell plasticity</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">immune escape</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">individual cell‐based modeling</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Neoplasms. Tumors. Oncology. Including cancer and carcinogens</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Computer applications to medicine. Medical informatics</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Changrong Shao</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Xiaopei Jiao</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yue Bai</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Miao Li</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hanping Shi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jinzhi Lei</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Xiaosong Zhong</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Computational and Systems Oncology</subfield><subfield code="d">Wiley, 2021</subfield><subfield code="g">1(2021), 3, Seite n/a-n/a</subfield><subfield code="w">(DE-627)1753559456</subfield><subfield code="w">(DE-600)3059855-2</subfield><subfield code="x">26899655</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:1</subfield><subfield code="g">year:2021</subfield><subfield code="g">number:3</subfield><subfield code="g">pages:n/a-n/a</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1002/cso2.1029</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/ebaa24c0803b4f1d8833b7c316639ecf</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1002/cso2.1029</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2689-9655</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_171</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_636</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2004</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2007</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2010</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2026</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2027</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2034</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2038</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2049</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2050</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2056</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2057</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2059</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2061</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2064</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2068</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2088</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2106</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2108</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2118</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2122</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2143</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2144</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2147</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2148</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2153</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2232</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2470</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2507</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2522</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4035</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4046</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4242</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4251</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4326</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4333</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4334</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4335</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">1</subfield><subfield code="j">2021</subfield><subfield code="e">3</subfield><subfield code="h">n/a-n/a</subfield></datafield></record></collection>
|
callnumber-first |
R - Medicine |
author |
Can Zhang |
spellingShingle |
Can Zhang misc RC254-282 misc R858-859.7 misc B‐cell acute lymphoblastic leukemia misc cancer immunotherapy misc CAR‐T misc cell plasticity misc immune escape misc individual cell‐based modeling misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens misc Computer applications to medicine. Medical informatics Individual cell‐based modeling of tumor cell plasticity‐induced immune escape after CAR‐T therapy |
authorStr |
Can Zhang |
ppnlink_with_tag_str_mv |
@@773@@(DE-627)1753559456 |
format |
electronic Article |
delete_txt_mv |
keep |
author_role |
aut aut aut aut aut aut aut aut |
collection |
DOAJ |
remote_str |
true |
callnumber-label |
RC254-282 |
illustrated |
Not Illustrated |
issn |
26899655 |
topic_title |
RC254-282 R858-859.7 Individual cell‐based modeling of tumor cell plasticity‐induced immune escape after CAR‐T therapy B‐cell acute lymphoblastic leukemia cancer immunotherapy CAR‐T cell plasticity immune escape individual cell‐based modeling |
topic |
misc RC254-282 misc R858-859.7 misc B‐cell acute lymphoblastic leukemia misc cancer immunotherapy misc CAR‐T misc cell plasticity misc immune escape misc individual cell‐based modeling misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens misc Computer applications to medicine. Medical informatics |
topic_unstemmed |
misc RC254-282 misc R858-859.7 misc B‐cell acute lymphoblastic leukemia misc cancer immunotherapy misc CAR‐T misc cell plasticity misc immune escape misc individual cell‐based modeling misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens misc Computer applications to medicine. Medical informatics |
topic_browse |
misc RC254-282 misc R858-859.7 misc B‐cell acute lymphoblastic leukemia misc cancer immunotherapy misc CAR‐T misc cell plasticity misc immune escape misc individual cell‐based modeling misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens misc Computer applications to medicine. Medical informatics |
format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
format_main_str_mv |
Text Zeitschrift/Artikel |
carriertype_str_mv |
cr |
hierarchy_parent_title |
Computational and Systems Oncology |
hierarchy_parent_id |
1753559456 |
hierarchy_top_title |
Computational and Systems Oncology |
isfreeaccess_txt |
true |
familylinks_str_mv |
(DE-627)1753559456 (DE-600)3059855-2 |
title |
Individual cell‐based modeling of tumor cell plasticity‐induced immune escape after CAR‐T therapy |
ctrlnum |
(DE-627)DOAJ06271841X (DE-599)DOAJebaa24c0803b4f1d8833b7c316639ecf |
title_full |
Individual cell‐based modeling of tumor cell plasticity‐induced immune escape after CAR‐T therapy |
author_sort |
Can Zhang |
journal |
Computational and Systems Oncology |
journalStr |
Computational and Systems Oncology |
callnumber-first-code |
R |
lang_code |
eng |
isOA_bool |
true |
recordtype |
marc |
publishDateSort |
2021 |
contenttype_str_mv |
txt |
author_browse |
Can Zhang Changrong Shao Xiaopei Jiao Yue Bai Miao Li Hanping Shi Jinzhi Lei Xiaosong Zhong |
container_volume |
1 |
class |
RC254-282 R858-859.7 |
format_se |
Elektronische Aufsätze |
author-letter |
Can Zhang |
doi_str_mv |
10.1002/cso2.1029 |
author2-role |
verfasserin |
title_sort |
individual cell‐based modeling of tumor cell plasticity‐induced immune escape after car‐t therapy |
callnumber |
RC254-282 |
title_auth |
Individual cell‐based modeling of tumor cell plasticity‐induced immune escape after CAR‐T therapy |
abstract |
Abstract Chimeric antigen receptor (CAR) therapy targeting CD19 is an effective treatment for refractory B cell malignancies, especially B‐cell acute lymphoblastic leukemia (B‐ALL). The majority of patients achieve a complete response following a single infusion of CD19‐targeted CAR‐modified T cells (CAR‐19 T cells); however, many patients suffer relapse after therapy, and the underlying mechanism remains unclear. To better understand the mechanism of tumor relapse, we developed an individual cell‐based computational model based on major assumptions of the tumor cells heterogeneity and plasticity as well as the heterogeneous responses to CAR‐T treatment. Model simulations reproduced the process of tumor relapse and predicted that cell plasticity induced by CAR‐T stress can lead to tumor relapse in B‐ALL. Model predictions were in agreement with experimental results of applying the second‐generation CAR‐T cells to mice injected with NALM‐6‐GL leukemic cells, in which 60% of the mice relapse within 3 months, relapsed tumors retained CD19 expression but exhibited a subpopulation of cells with high level CD34 transcription. The computational model suggests that the experimental data are compatible with a CAR‐T cell‐induced transition of tumor cells to hematopoietic stem‐like cells and myeloid‐like cells, which are resistant to the treatment. The proposed computational model framework was successfully developed to recapitulate the individual evolutionary dynamics and potentially allows to predict the outcomes of CAR‐T treatment through model simulation based on early‐stage observations of tumor burden and tumor cells analysis. |
abstractGer |
Abstract Chimeric antigen receptor (CAR) therapy targeting CD19 is an effective treatment for refractory B cell malignancies, especially B‐cell acute lymphoblastic leukemia (B‐ALL). The majority of patients achieve a complete response following a single infusion of CD19‐targeted CAR‐modified T cells (CAR‐19 T cells); however, many patients suffer relapse after therapy, and the underlying mechanism remains unclear. To better understand the mechanism of tumor relapse, we developed an individual cell‐based computational model based on major assumptions of the tumor cells heterogeneity and plasticity as well as the heterogeneous responses to CAR‐T treatment. Model simulations reproduced the process of tumor relapse and predicted that cell plasticity induced by CAR‐T stress can lead to tumor relapse in B‐ALL. Model predictions were in agreement with experimental results of applying the second‐generation CAR‐T cells to mice injected with NALM‐6‐GL leukemic cells, in which 60% of the mice relapse within 3 months, relapsed tumors retained CD19 expression but exhibited a subpopulation of cells with high level CD34 transcription. The computational model suggests that the experimental data are compatible with a CAR‐T cell‐induced transition of tumor cells to hematopoietic stem‐like cells and myeloid‐like cells, which are resistant to the treatment. The proposed computational model framework was successfully developed to recapitulate the individual evolutionary dynamics and potentially allows to predict the outcomes of CAR‐T treatment through model simulation based on early‐stage observations of tumor burden and tumor cells analysis. |
abstract_unstemmed |
Abstract Chimeric antigen receptor (CAR) therapy targeting CD19 is an effective treatment for refractory B cell malignancies, especially B‐cell acute lymphoblastic leukemia (B‐ALL). The majority of patients achieve a complete response following a single infusion of CD19‐targeted CAR‐modified T cells (CAR‐19 T cells); however, many patients suffer relapse after therapy, and the underlying mechanism remains unclear. To better understand the mechanism of tumor relapse, we developed an individual cell‐based computational model based on major assumptions of the tumor cells heterogeneity and plasticity as well as the heterogeneous responses to CAR‐T treatment. Model simulations reproduced the process of tumor relapse and predicted that cell plasticity induced by CAR‐T stress can lead to tumor relapse in B‐ALL. Model predictions were in agreement with experimental results of applying the second‐generation CAR‐T cells to mice injected with NALM‐6‐GL leukemic cells, in which 60% of the mice relapse within 3 months, relapsed tumors retained CD19 expression but exhibited a subpopulation of cells with high level CD34 transcription. The computational model suggests that the experimental data are compatible with a CAR‐T cell‐induced transition of tumor cells to hematopoietic stem‐like cells and myeloid‐like cells, which are resistant to the treatment. The proposed computational model framework was successfully developed to recapitulate the individual evolutionary dynamics and potentially allows to predict the outcomes of CAR‐T treatment through model simulation based on early‐stage observations of tumor burden and tumor cells analysis. |
collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_206 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_636 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2068 GBV_ILN_2088 GBV_ILN_2106 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2118 GBV_ILN_2122 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2470 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_4012 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 |
container_issue |
3 |
title_short |
Individual cell‐based modeling of tumor cell plasticity‐induced immune escape after CAR‐T therapy |
url |
https://doi.org/10.1002/cso2.1029 https://doaj.org/article/ebaa24c0803b4f1d8833b7c316639ecf https://doaj.org/toc/2689-9655 |
remote_bool |
true |
author2 |
Changrong Shao Xiaopei Jiao Yue Bai Miao Li Hanping Shi Jinzhi Lei Xiaosong Zhong |
author2Str |
Changrong Shao Xiaopei Jiao Yue Bai Miao Li Hanping Shi Jinzhi Lei Xiaosong Zhong |
ppnlink |
1753559456 |
callnumber-subject |
RC - Internal Medicine |
mediatype_str_mv |
c |
isOA_txt |
true |
hochschulschrift_bool |
false |
doi_str |
10.1002/cso2.1029 |
callnumber-a |
RC254-282 |
up_date |
2024-07-03T13:39:36.630Z |
_version_ |
1803565375572410368 |
fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ06271841X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230309022646.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230228s2021 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1002/cso2.1029</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ06271841X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJebaa24c0803b4f1d8833b7c316639ecf</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC254-282</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">R858-859.7</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Can Zhang</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Individual cell‐based modeling of tumor cell plasticity‐induced immune escape after CAR‐T therapy</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Chimeric antigen receptor (CAR) therapy targeting CD19 is an effective treatment for refractory B cell malignancies, especially B‐cell acute lymphoblastic leukemia (B‐ALL). The majority of patients achieve a complete response following a single infusion of CD19‐targeted CAR‐modified T cells (CAR‐19 T cells); however, many patients suffer relapse after therapy, and the underlying mechanism remains unclear. To better understand the mechanism of tumor relapse, we developed an individual cell‐based computational model based on major assumptions of the tumor cells heterogeneity and plasticity as well as the heterogeneous responses to CAR‐T treatment. Model simulations reproduced the process of tumor relapse and predicted that cell plasticity induced by CAR‐T stress can lead to tumor relapse in B‐ALL. Model predictions were in agreement with experimental results of applying the second‐generation CAR‐T cells to mice injected with NALM‐6‐GL leukemic cells, in which 60% of the mice relapse within 3 months, relapsed tumors retained CD19 expression but exhibited a subpopulation of cells with high level CD34 transcription. The computational model suggests that the experimental data are compatible with a CAR‐T cell‐induced transition of tumor cells to hematopoietic stem‐like cells and myeloid‐like cells, which are resistant to the treatment. The proposed computational model framework was successfully developed to recapitulate the individual evolutionary dynamics and potentially allows to predict the outcomes of CAR‐T treatment through model simulation based on early‐stage observations of tumor burden and tumor cells analysis.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">B‐cell acute lymphoblastic leukemia</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">cancer immunotherapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">CAR‐T</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">cell plasticity</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">immune escape</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">individual cell‐based modeling</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Neoplasms. Tumors. Oncology. Including cancer and carcinogens</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Computer applications to medicine. Medical informatics</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Changrong Shao</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Xiaopei Jiao</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yue Bai</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Miao Li</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hanping Shi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jinzhi Lei</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Xiaosong Zhong</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Computational and Systems Oncology</subfield><subfield code="d">Wiley, 2021</subfield><subfield code="g">1(2021), 3, Seite n/a-n/a</subfield><subfield code="w">(DE-627)1753559456</subfield><subfield code="w">(DE-600)3059855-2</subfield><subfield code="x">26899655</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:1</subfield><subfield code="g">year:2021</subfield><subfield code="g">number:3</subfield><subfield code="g">pages:n/a-n/a</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1002/cso2.1029</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/ebaa24c0803b4f1d8833b7c316639ecf</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1002/cso2.1029</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2689-9655</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_171</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_636</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2004</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2007</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2010</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2026</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2027</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2034</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2038</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2049</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2050</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2056</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2057</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2059</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2061</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2064</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2068</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2088</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2106</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2108</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2118</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2122</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2143</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2144</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2147</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2148</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2153</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2232</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2470</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2507</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2522</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4035</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4046</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4242</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4251</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4326</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4333</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4334</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4335</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">1</subfield><subfield code="j">2021</subfield><subfield code="e">3</subfield><subfield code="h">n/a-n/a</subfield></datafield></record></collection>
|
score |
7.400324 |